NASDAQ NMS - GLOBAL MARKET · KARD
+0.43% · +$0.0600 · Vol 45.1K
Live · updated 10:20:00 ET
Kardigan Inc

Kardigan Inc

Pharmaceuticals
$13.89
Card
Relationship Map

Follow $KARD

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $KARD by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Earnings absence reason unknown
KARD
Kardigan Inc
Wed Oct 7 · last completed session · daily score · 12h old
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

61/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Wed Oct 7 · last completed session · daily score · 12h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KARD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KARD catalysts
About Kardigan Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2026
Country
US

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$13.60
Day high
$14.17
Day low
$13.42
Previous close
$13.83
52W high
$25.90
-46.37% from high
52W low
$13.42
4% of range
Market cap
$1.3B
EPS
$-7.3893
Beta
1.77
Shares out
93.5M
Volume
45.1K
0.06× rel vol
Avg volume
759.1K
VWAP
$13.80
Price history computed in-house
1W
-2.53%
1M
-35.69%
3M
-43.62%
SMA 50 $18.80 · below
SMA 200 Not reported · Not reported
52W position 4%

KARD overview

Veridion Score
61
Registered · 2026-10-07
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KARD.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KARD Form 4 filings
Public disclosures

Congress activity in KARD

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

KARD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KARD in this window.
Lobbying spend

KARD lobbying filings, year to date.

Registered lobbying filings matched to Kardigan Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KARD in this window.
Loading news for KARD
Analyst ratings
Sovereign unlock shows live analyst consensus for KARD.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.